Enrique Soto Perez de Celis Shares New Findings on DPYD Variation in Mexican Patients with Gastrointestinal Cancers
A new study published in Cancer Chemotherapy and Pharmacology reveals that actionable DPYD genetic variants are significantly less frequent in Mexican patients compared to European populations. The findings emphasize the need for more diverse pharmacogenomic research to ensure equitable precision medicine.
Why it matters
Current medical dosing algorithms are often based on European data, which may lead to inaccurate treatments for admixed populations, highlighting a gap in healthcare equity.
Enrique Soto Perez de Celis , Associate Professor at University of Colorado Anschutz, shared on LinkedIn :
“Excited to share our new paper on DPYD pharmacogenetic variation in Mexican patients with gastrointestinal cancers, now published in Cancer Chemotherapy and Pharmacology .
One of the most striking findings: actionable DPYD variants were about 10-fold less frequent in admixed Mexican populations than in European-ancestry populations. This matters because many current pharmacogenetic tests and dosing recommendations are based largely on European-derived data. Our results suggest that the variants and algorithms we currently use may not translate equally well to admixed populations – an important consideration as we work toward truly equitable precision medicine.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in